HALOZYME THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
HALOZYME THERAPEUTICS, INC. (HALO) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of -$63.80 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2019-02-21
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-12-31 was -$18.35M, a 22482.93% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-09-30 was -$16.42M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-06-30 was -$16.37M, a 112.05% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-03-31 was -$12.65M.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2018 was -$63.80M, a 148.46% decline from fiscal 2017.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $131.66M, a 12.59% decline from fiscal 2016.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $150.62M, a 1049.95% increase from fiscal 2015.
- HALOZYME THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $13.10M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$18.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$34.77M derived: sum of 2 quarters · filed 2019-02-21 | -$51.15M derived: sum of 3 quarters · filed 2019-02-21 | -$63.80M 10-K · filed 2019-02-21 |
| 2018-09-30 | -$16.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$32.79M derived: sum of 2 quarters · filed 2018-11-06 | -$45.44M 10-Q · filed 2018-11-06 | -$45.36M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-06-30 | -$16.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$29.02M 10-Q · filed 2018-08-07 | -$28.94M derived: sum of 3 quarters · filed 2019-02-21 | -$29.83M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-03-31 | -$12.65M 10-Q · filed 2018-05-10 | -$12.57M derived: sum of 2 quarters · filed 2019-02-21 | -$13.46M derived: sum of 3 quarters · filed 2019-02-21 | $122.39M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$808.00K derived: sum of 2 quarters · filed 2019-02-21 | $135.04M derived: sum of 3 quarters · filed 2019-02-21 | $131.66M 10-K · filed 2019-02-21 |
| 2017-09-30 | -$890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $134.96M derived: sum of 2 quarters · filed 2018-11-06 | $131.57M 10-Q · filed 2018-11-06 | $131.85M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-06-30 | $135.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $132.46M 10-Q · filed 2018-08-07 | $132.74M derived: sum of 3 quarters · filed 2019-02-21 | $133.22M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-03-31 | -$3.38M 10-Q · filed 2018-05-10 | -$3.10M derived: sum of 2 quarters · filed 2019-02-21 | -$2.63M derived: sum of 3 quarters · filed 2019-02-21 | $2.79M derived: sum of 4 quarters · filed 2019-02-21 |
| 2016-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $755.00K derived: sum of 2 quarters · filed 2019-02-21 | $6.17M derived: sum of 3 quarters · filed 2019-02-21 | $150.62M 10-K · filed 2019-02-21 |
| 2016-09-30 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.90M derived: sum of 2 quarters · filed 2017-11-07 | $150.34M 10-Q · filed 2017-11-07 | $152.07M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $149.87M 10-Q · filed 2017-08-08 | $151.60M derived: sum of 3 quarters · filed 2018-02-20 | $152.03M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $144.45M 10-Q · filed 2017-05-09 | $146.18M derived: sum of 2 quarters · filed 2018-02-20 | $146.61M derived: sum of 3 quarters · filed 2018-02-20 | $150.39M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $2.17M derived: sum of 2 quarters · filed 2018-02-20 | $5.94M derived: sum of 3 quarters · filed 2018-02-20 | $13.10M 10-K · filed 2018-02-20 |
| 2015-09-30 | $437.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $4.21M derived: sum of 2 quarters · filed 2016-11-07 | $11.37M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $10.93M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $7.16M 10-Q · filed 2016-05-09 | |||
| 2014-09-30 | $112.03M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |